UNAUDITED INTERIM
RESULTS
for the six months ended
31 December
2022
RE-IMAGINING
THE HEALTHCARE
SYSTEM
THE HEALTHCARE
SYSTEM
| EXCEL DOWNLOAD |
| % change |
Unaudited six months ended 31 December 2022 R'000 |
Restated* Unaudited six months ended 31 December 2021 R'000 |
Audited year ended 30 June 2022 R'000 |
|
| Revenue from contracts with customers | 1.2 | 4 322 145 | 4 269 641 | 8 693 217 |
|---|---|---|---|---|
| Fair value gains | 4 462 | 4 700 | 6 369 | |
| Finance income | 9 085 | 7 402 | 14 996 | |
| Other income | — | — | 563 | |
| Total income | 1.3 | 4 335 692 | 4 281 743 | 8 715 145 |
| Cost of distribution of pharmaceutical products | (42 469) | (53 099) | (98 694) | |
| Cost of pharmaceutical products and finished goods | (973 434) | (935 167) | (2 022 726) | |
| Employee benefit costs | (1 168 278) | (1 166 984) | (2 340 458) | |
| Other expenses | (1 481 404) | (1 469 917) | (2 880 066) | |
| Amortisation | (107 047) | (114 272) | (231 269) | |
| Rent and property costs | (49 830) | (47 631) | (95 137) | |
| Right of use assets depreciation | (31 320) | (25 284) | (61 606) | |
| Depreciation | (43 666) | (41 189) | (87 138) | |
| IT costs | (128 710) | (65 355) | (145 734) | |
| Write off of intangible assets | — | — | (635) | |
| Impairment of loans | — | (3 108) | (3 203) | |
| Share of profits from associates and joint ventures | 5 325 | 4 378 | 6 991 | |
| Interest on lease liabilities | (7 749) | (8 686) | (18 781) | |
| Finance costs | (36 162) | (28 132) | (57 049) | |
| Profit before tax | (17.2) | 270 948 | 327 297 | 679 640 |
| Income tax expense – continuing operations | 15.2 | (76 504) | (90 179) | (190 963) |
| Profit from continuing operations | (18.0) | 194 444 | 237 118 | 488 677 |
| Loss from discontinued operations (NOTE 5) | — | (3 489) | (6 937) | |
| Loss on disposal of subsidiaries (NOTE 5) | (198) | — | — | |
| Profit for the year | (16.9) | 194 246 | 233 629 | 481 740 |
| Profit for the year attributable to: | ||||
| Owners of Parent | 125 793 | 154 281 | 314 276 | |
| Non-controlling interest | 68 453 | 79 348 | 167 464 | |
| (16.9) | 194 246 | 233 629 | 481 740 | |
| Profit for the year attributable to equity shareholders arises from: | ||||
| Continuing operations | 125 793 | 157 770 | 321 213 | |
| Discontinued operations | — | (3 489) | (6 937) | |
| (18.5) | 125 793 | 154 281 | 314 276 | |
| Profit for the year | (16.9) | 194 246 | 233 629 | 481 740 |
| Other comprehensive income | ||||
| Components of other comprehensive income that will not be reclassified to profit or loss | ||||
| Remeasurement of post-employment benefit obligations | — | — | (24) | |
| Income tax relating to these items | — | — | 6 | |
| Total other comprehensive income that will not be reclassified to profit or loss | — | — | (18) | |
| Components of other comprehensive income that will be reclassified to profit or loss | ||||
| Foreign exchange benefit of continuing operations | 2 853 | 1 703 | 1 519 | |
| Total other comprehensive income that will be reclassified to profit or loss | 2 853 | 1 703 | 1 519 | |
| Total other comprehensive income net of tax | 2 853 | 1 703 | 1 501 | |
| Total comprehensive income | (16.2) | 197 099 | 235 332 | 483 241 |
| Comprehensive income attributable to: | ||||
| Comprehensive income, attributable to owners of parent | 127 827 | 155 495 | 315 341 | |
| Comprehensive income, attributable to non- controlling interests | 69 272 | 79 837 | 167 900 | |
| 197 099 | 235 332 | 483 241 |
| * | Refer to note 4 for the details of the restatement |